OpenEvidence vs Tempus AI vs Nabla vs Abridge
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
|
|
|
Nabla
Ambient AI scribe that turns patient visits into clinical notes.
Visit
|
Abridge
Ambient AI scribe for clinicians — 200+ health systems, Best in KLAS
Visit
|
|
|---|---|---|---|---|
| RECATOOLS Score | 7.8 / 10 | 8.2 / 10 | 8.2 / 10 | 8.2 / 10 |
| Capability | ||||
| Value for money | ||||
| Ease of use | ||||
| ASEAN readiness | ||||
| API quality | ||||
| Pricing | Freemium | Enterprise | Freemium | Enterprise |
| Free tier | Free for all verified US clinicians (NPI required); ad-supported | No free tier; enterprise contracts only | Free trial available with core documentation features and limited usage | None — enterprise contracts only, no self-serve or trial tier |
| Paid from | Enterprise tier in development; pricing undisclosed — contact sales | Custom enterprise contracts; multi-year data-licensing subscriptions (price not publicly disclosed) | Free tier (up to 30 consultations/mo); Pro ~$119/month (unlimited); enterprise via contract | Enterprise quote only; no public self-serve pricing (12-month minimum) |
| Has API | ✗ | ✓ | ✓ | ✗ |
| Open source | ✗ | ✗ | ✗ | ✗ |
| Free to use | ✓ | ✗ | ✗ | ✗ |
| Users | ~860,000 verified US clinicians (June 2026) | ~50% of US oncologists; 4,500+ hospital integrations; 40M+ clinical records | 85,000+ clinicians across 150+ health organisations (mid-2025) | 200+ health systems; ~50-80M clinical conversations/year |
| Founded | 2022 | 2015 | 2018 | 2018 |
| Maker | Daniel Nadler (CEO), Zachary Ziegler (CTO) | Tempus AI, Inc. (independent, Nasdaq: TEM) | Nabla Technologies | Abridge AI, Inc. (independent) |
| Verdict | OpenEvidence is genuinely useful for US clinicians: free, citation-backed answers pulled from NEJM, JAMA, and AMA guidelines, funded by pharma advertising instead of subscriptions. Growth has been extraordinary — over 69... |
Tempus AI sits on one of the more defensible data moats in health AI — a self-reinforcing loop of clinical sequencing, molecular data, and real-world outcomes that's hard for pure-software competitors to replicate. Q1 20... |
Nabla has the best clinical evidence in ambient scribing: a NEJM AI randomized trial across 238 physicians and 48,000+ visits found a statistically significant 9.5% cut in documentation time. Real deployments back it up... |
Abridge is the clear market leader in ambient AI documentation for large US health systems, validated by more peer-reviewed research than any competitor, Best in KLAS two consecutive years, and deployments at the most pr... |
| Full review → | Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.